Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
Jul 2021Asthma
Nov 2021Atopic Dermatitis
Jul 2021Hereditary Angioedema
Jul 2021Hypertrophic Cardiomyopathy
Oct 2021Lupus Nephritis
Mar 2021Multiple Myeloma
Apr 2021Myasthenia Gravis
Sep 2021Featured News & Insights.
Learn about our latest work.
ICER to Assess Treatment for Severe Asthma
— Report will be subject of Midwest CEPAC meeting in November 2021; Draft Scoping Document open to public comment until May 27, 2021 – BOSTON, May 6, 2021 – The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of tezepelumab (AstraZeneca) for the treatment of severe […]
05/06/2021ICER Releases Draft Evidence Report on Aducanumab for Alzheimer’s Disease
Given the risk of side effects and the uncertainty of benefit, ICER assigns a draft rating of “insufficient” to the strength of evidence on whether aducanumab provides a net health benefit for patients. Results are preliminary and subject to change based on public comment, which ICER is accepting through June 2, 2021.
05/05/2021ICER Publishes White Paper Evaluating Policy Options to Strengthen FDA’s Accelerated Approval Pathway for Prescription Drugs
Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyzes potential impact of a variety of reform options that address the balance between uncertainty, access, innovation, and costs.
04/26/2021The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.
Strengthening the FDA’s Accelerated Approval Pathway
This paper aims to create a clearer understanding of both the opportunities and challenges inherent in the FDA’s accelerated approval pathway (AAP), and to present an analysis of the potential risks and benefits of a range of reform options that policymakers may consider in efforts to strengthen the AAP moving forward.
Cornerstones of ‘Fair’ Drug Coverage
Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, this white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.
Latest
Developments.
We’re hiring! Click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.